Kemkes-Matthes B
Zentrum für Innere Medizin, Universität Giessen.
Zentralbl Chir. 2001 Jun;126(6):433-7. doi: 10.1055/s-2001-14762.
Using laboratory testing, coagulation alterations can be detected in about 50% of familial thrombophilia. Most common hereditary coagulation defects leading to enhanced thrombosis risk are aPC resistance/Factor V Leiden mutation, protein C- and S-deficiency, prothrombin 20210A polymorphism and antithrombin deficiency. Moreover, elevated plasma levels of homocysteine also are associated with enhanced thrombosis risk. Severity of thromboembolic risk depends upon type of coagulation defect, hetero- or homocygosity and occurrence of additional acquired risk factors like immobilisation. Therapy of thromboembolic diseases must always be planned considering both clinical circumstances and laboratory findings.
通过实验室检测,约50%的家族性血栓形成倾向患者可检测到凝血异常。导致血栓形成风险增加的最常见遗传性凝血缺陷是活化蛋白C抵抗/凝血因子V莱顿突变、蛋白C和S缺乏、凝血酶原20210A多态性以及抗凝血酶缺乏。此外,血浆同型半胱氨酸水平升高也与血栓形成风险增加有关。血栓栓塞风险的严重程度取决于凝血缺陷的类型、杂合性或纯合性以及是否存在诸如制动等其他获得性风险因素。血栓栓塞性疾病的治疗必须始终根据临床情况和实验室检查结果进行规划。